Multicenter 3-arm Trial to Evaluate the Efficacy and Safety of Pasireotide LAR or Everolimus Alone or in Combination in Patients With Well Differentiated Neuroendocrine Carcinoma of the Lung and Thymus - LUNA Trial.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Everolimus (Primary) ; Pasireotide (Primary)
- Indications Lung cancer; Malignant thymoma; Neuroendocrine carcinoma
- Focus Therapeutic Use
- Acronyms LUNA
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 23 Oct 2017 Results published in the Lancet Oncology Journal.
- 06 Mar 2017 Planned End Date changed from 1 Oct 2016 to 30 Nov 2017.
- 06 Mar 2017 Planned primary completion date changed from 1 Oct 2016 to 30 Nov 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History